

28th October, 2020

BSE Limited

P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 500302, 912460

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PEL

Sub: Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2020

Dear Sir / Madam,

Kindly refer to our letter dated 21st October, 2020 on the subject.

At its meeting held today, the Board approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended 30th September, 2020.

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('Listing Regulations') we enclose the following:

1. Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September, 2020;
2. Limited Review Report by the Auditors; and
3. Press Release and Presentation to the investors.

We are arranging to publish these results in the newspapers as per Regulation 47 of Listing Regulations.

The meeting commenced at 11:15 a.m. and concluded at 2:00 p.m.

Request you to please take the above on record and oblige.

Thanking you,

Yours truly,

For **Piramal Enterprises Limited**

Bipin Singh
Company Secretary

Encl.: a/a

Piramal Enterprises Limited

CIN : L24110MH1947PLC005719

Registered Office: Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Mag, Kurla (West), Mumbai 400 070 India
Secretarial Dept : Ground Floor, B Block, Agastya Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, Maharashtra 400070, India

T +91 22 3802 3084/3083/3103 F +91 22 3802 3084

piramal.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

**TO THE BOARD OF DIRECTORS OF
PIRAMAL ENTERPRISES LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **PIRAMAL ENTERPRISES LIMITED** ("the Company"), for the quarter and six months ended September 30, 2020 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. As more fully described in Note 5 (a) to the Statement, to assess the recoverability of certain assets, the Company has considered internal and external information upto the date of this report in respect of the current and estimated future global including Indian economic indicators consequent to the global health pandemic. The actual impact of the pandemic may be different from that considered in assessing the recoverability of these assets.

Our conclusion on the Statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Rupen K. Bhatt
Partner
(Membership No. 046930)

Place: Mumbai
Date: October 28, 2020

PIRAMAL ENTERPRISES LIMITED

Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400 070

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2020

Particulars	(Rs.in Crores)					
	Three months ended 30/09/2020	Three months ended 30/06/2020	Corresponding three months ended 30/09/2019	Year to date figures for current period ended 30/09/2020	Year to date figures for current period ended 30/09/2019	Previous Year ended 31/03/2020
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Revenue from operations	1,026.45	817.41	1,443.04	1,843.86	2,314.81	4,219.19
Other income (Net) (Refer Note 7 & 8)	92.71	38.52	189.39	131.23	256.89	699.06
Total Income	1,119.16	855.93	1,632.43	1,975.09	2,571.70	4,918.25
Expenses						
Cost of materials consumed	293.53	229.71	229.32	523.24	421.74	878.18
Purchases of stock-in-trade	44.50	20.49	0.17	64.99	17.36	75.92
Changes in inventories of finished goods, stock-in-trade and work-in-progress	(70.86)	(45.39)	(17.29)	(116.25)	(37.28)	(10.73)
Employee benefits expense	106.09	120.92	116.68	227.01	236.93	463.15
Finance costs	345.95	287.92	456.95	633.87	944.62	1,710.06
Depreciation and amortisation expense	38.14	40.67	41.94	78.81	81.97	175.46
Expected Credit Loss on Financial Assets (including Commitments) (Refer Note 5 (b))	(0.39)	1.51	(19.08)	1.12	(14.14)	327.88
Other expenses (Net) (Refer Note 7)	203.54	173.04	178.19	376.58	374.93	758.49
Total Expenses	960.50	828.87	986.88	1,789.37	2,026.13	4,378.41
Profit Before Exceptional Item and Tax	158.66	27.06	645.55	185.72	545.57	539.84
Exceptional item (Refer note 9)	(37.42)	-	-	(37.42)	-	-
Profit Before Tax	121.24	27.06	645.55	148.30	545.57	539.84
Tax Expense						
(1) Current tax	4.27	3.05	(6.35)	7.32	104.16	130.42
(2) Deferred tax (Net)	13.66	1.47	18.80	15.13	(150.99)	(121.05)
(3) Tax adjustment for earlier years (Refer Note 10)	-	-	-	-	-	385.62
Profit After Tax	103.31	22.54	633.10	125.85	592.40	144.85
Other Comprehensive Income and (Expense) (OCI)						
A. Items that will not be subsequently reclassified to profit or loss						
(a) Changes in fair values of equity instruments through OCI	182.49	(50.70)	(184.55)	131.79	(969.54)	(1,359.46)
(b) Remeasurement of Post Employment Benefit Obligations	(0.69)	0.01	0.67	(0.68)	(2.04)	(3.21)
Income tax impact on above	0.17	(0.00)	(0.26)	0.17	0.70	0.81
B. Items that will be subsequently reclassified to profit or loss						
Deferred gain / (loss) on cash flow hedge	15.61	6.81	(6.52)	22.42	(6.14)	(24.01)
Income tax impact on above	(4.47)	(1.17)	2.28	(5.64)	2.15	6.04
Total Other Comprehensive Income / (Expense) , Net of Tax Expense	193.11	(45.05)	(188.38)	148.06	(974.86)	(1,379.83)
Total Comprehensive Income / (Loss), Net of Tax Expense	296.42	(22.51)	444.72	273.91	(382.46)	(1,234.98)
Paid-up Equity Share Capital (Face Value of Rs.2/- each)	45.11	45.11	39.77	45.11	36.68	45.11
Reserves (excluding Revaluation Reserves)						22,582.87
Net Worth (Refer Footnote)				20,206.36	16,158.03	20,248.25
Paid up Debt Capital				5,666.00	6,259.05	4,404.40
Debt Redemption Reserve				822.52	1,516.88	655.79
Earnings Per Equity Share (EPS) (Face Value of Rs.2/- each) (not annualised)						
a) Basic EPS for the period/year (Rs.)	4.36	0.95	31.07	5.31	29.08	6.87
b) Diluted EPS for the period/year (Rs.)	4.32	0.94	30.98	5.26	28.99	6.84
Debt Equity Ratio (Refer Footnote 2)				0.5	0.7	0.5
Debt Service Coverage Ratio (Refer Footnote 3)				0.3	0.3	0.2
Interest Service Coverage Ratio (Refer Footnote 4)				1.3	1.6	1.3

Footnote:

- Net Worth = Share Capital + Other Equity (excluding Capital Reserve)
- Debt equity Ratio:
Debt = Long term Borrowings + Short term Borrowings + Current maturities of Long term Borrowings
Equity = Paid up Share Capital+ Other Equity
- Debt Service Coverage Ratio = (Earnings before Interest, Tax and Exceptional items) / (Interest Expense + Principal Repayment of Debt excluding loans transferred)
Debt = Long Term Debt
Interest Expense = Interest on Long Term Debt
- Interest Service Coverage Ratio = (Earnings before Interest, Tax and Exceptional items) / Interest Expense



Additional Information:

The following additional information is presented to disclose the effect on net profit after tax, Basic and Diluted EPS, without the effect of tax adjustment of prior years (Refer Note 10).

Particulars	(Rs. in Crores)
	Previous year ended 31/03/2020
Profit After Tax As reported in the standalone financial results	144.85
Add: Impact of Tax adjustment of prior years	385.62
Adjusted Profit After Tax	530.47
Basic EPS for the period (Rs.)	
As reported in the standalone financial results	6.87
Add: Impact of Tax adjustment of prior years	18.30
Adjusted Basic EPS	25.17
Diluted EPS for the period (Rs.)	
As reported in the standalone financial results	6.84
Add: Impact of Tax adjustment of prior years	18.22
Adjusted Diluted EPS	25.06



Notes:

1. The unaudited standalone financial results for the six and three months ended September 30, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 28, 2020. The Statutory auditors of the Company have carried out a limited review of these results.

2. Statement of Standalone Assets and Liabilities :
(Rs.in Crores)

Particulars	As at	
	30/09/2020	31/03/2020
	(Unaudited)	(Audited) (Refer note 12)
ASSETS		
1. Non-Current Assets		
(a) Property, Plant & Equipment	1,344.18	1,384.79
(b) Capital Work in Progress	86.92	62.80
(c) Intangible Assets	343.36	357.54
(d) Intangible Assets under development	35.87	56.63
(e) Right-of-use assets	36.95	46.93
(f) Financial Assets:		
(i) Investments	18,723.60	18,452.21
(ii) Loans	9,041.38	10,869.25
(iii) Other Financial Assets	841.90	23.70
(g) Deferred Tax Assets (Net)	12.97	34.88
(h) Other Non-Current Assets	504.28	456.25
Total Non-Current Assets	30,971.41	31,744.98
2. Current Assets		
(a) Inventories	600.38	423.56
(b) Financial Assets:		
(i) Investments	1,059.16	986.71
(ii) Trade Receivables	520.30	657.10
(iii) Cash & Cash equivalents	1,048.64	43.66
(iv) Bank balances other than (iii) above	70.60	35.08
(v) Loans	778.75	80.12
(vi) Other Financial Assets	89.85	95.16
(c) Assets held for sale	-	10.00
(d) Other Current Assets	486.75	399.50
Total Current Assets	4,654.43	2,730.89
Total Assets	35,625.84	34,475.87
EQUITY AND LIABILITIES		
1. Equity		
(a) Equity Share capital	45.11	45.11
(b) Other Equity	22,548.07	22,582.87
Total Equity	22,593.18	22,627.98
2. Liabilities		
Non-Current Liabilities		
(a) Financial Liabilities:		
(i) Borrowings	3,521.04	2,389.78
(ii) Lease liabilities	18.25	22.90
(b) Provisions	51.88	47.24
(c) Deferred Tax Liabilities	-	-
(c) Other Non-Current Liabilities	103.29	141.75
Total Non-Current Liabilities	3,694.46	2,601.67
Current Liabilities		
(a) Financial Liabilities:		
(i) Borrowings	4,343.53	4,061.75
(ii) Lease liabilities	13.71	19.90
(iii) Trade Payables		
(a) Total outstanding dues of Micro enterprises and small enterprises	8.75	11.86
(b) Total outstanding dues of creditors other than Micro enterprises and small enterprises	720.94	605.96
(iv) Other Financial Liabilities	3,912.73	4,228.43
	8,999.66	8,927.90
(b) Other Current Liabilities	145.34	125.41
(c) Provisions	46.97	46.17
(d) Current Tax Liabilities (Net)	146.23	146.74
Total Current Liabilities	9,338.20	9,246.22
Total Equity & Liabilities	35,625.84	34,475.87



Notes:

3. Unaudited Standalone cash flow information:

Particulars	(Rs. In Crores)	
	Year to date figures for current period ended 30/09/2020	Year to date figures for current period ended 30/09/2019
Cash flow from operating activities		
Profit Before Exceptional Item and Tax	185.72	545.57
Operating Profit before working capital changes	154.95	660.58
A. Net Cash generated from / (used in) Operating Activities*	(851.42)	4,041.95
B. Net Cash generated from investing Activities	1,260.15	768.37
C. Net Cash (used in) / generated from financing Activities	2,216.60	(4,548.05)
Net increase in Cash & Cash Equivalents (A+B+C)	2,625.33	262.27
Cash and cash equivalents (Net of Bank Overdraft)		
At the beginning of the period	(1,576.69)	(53.52)
At the end of the period	1,048.64	208.75

Footnote:

* Cash flow generated from / (used in) Operating Activities in the six months ended September 30, 2019 is not comparable with that of the previous period, due to the reason stated in note 13.

4. The Board of Directors ('Board') of the Company at their meeting held on June 26, 2020, had inter alia, approved:

a. the sale/ transfer of the pharmaceutical business ('Pharma Business') of the Company, held by the Company directly and through its wholly owned subsidiaries, to Piramal Pharma Limited, wholly owned subsidiary of the Company ('PPL').

b. the strategic growth investment by CA Clover Intermediate II Investments (now known as CA Alchemy Investments) ("Carlyle"), an affiliated entity of CAP V Mauritius Limited, an investment fund managed and advised by affiliated entities of The Carlyle Group Inc., for a 20% stake in the fresh equity capital of PPL.

This transaction was successfully closed on October 6th, 2020 on receipt of requisite approvals, As a result PPL, subsidiary of the Company received Rs.3,523.40 Crores towards 20% equity investment from CA Alchemy Investments.

5. Estimation of uncertainty relating to COVID-19 global health pandemic:

a) In assessing the recoverability of loans, receivables, intangible assets and investments, the Company has considered internal and external sources of information, including credit reports, economic forecasts and industry reports upto the date of approval of these standalone financial results. The Company has performed sensitivity analysis on the assumptions used and based on current indicators of future economic conditions, the carrying amount of these assets value represent the Company's best estimate of the recoverable amounts. As a result of uncertainties resulting from COVID-19 and external developments, including the final decision of the Honourable Supreme Court in relation to moratorium and other related matters, the impact of this pandemic may be different from those estimated as on the date of approval of these financial results and the Company will continue to monitor any changes to the future economic conditions.

b) During the year ended March 31, 2020, the Company had estimated and recognised an additional expected credit loss of Rs. 303 Crores on certain financial assets, on account of the anticipated effect of the global health pandemic.

6. The secured listed non-convertible debentures of the Company aggregating Rs.1,250 crores as on September 30, 2020 are secured against specified receivables (including those relating to a wholly owned subsidiary) and a first ranking pari passu mortgage over Specifically Mortgaged Property.

The Asset cover on the secured listed non-convertible debentures of the Company exceeds hundred percent of the principal amount of the said debentures.

7. Other Income/ Expenses (Net) includes the net effect of Foreign Exchange Gain/(Loss) :

Particulars	(Rs. in Crores)					
	Three months ended 30/09/2020	Three months ended 30/06/2020	Corresponding three months ended 30/09/2019	Year to date figures for current period ended 30/09/2020	Year to date figures for current period ended 30/09/2019	Previous Year ended 31/03/2020
Exchange Gain/(Loss), Net	(22.52)	7.04	81.42	(15.48)	79.22	236.80

8. During the year ended March 31,2020:

The Board of Directors of the Company, at their meeting held on January 17, 2020 approved the divestment of entire stake in the Healthcare Insights and Analytics business (the "Transaction"), held by the Company directly and through its wholly owned subsidiaries, to Clarivate Analytics Plc. (and its subsidiaries) for an aggregate consideration of USD 950 million of which USD 900 million would be received on closing of the Transaction and USD 50 million would be received at the end of 12 months from the closing of the Transaction. Closing of the transaction was completed on February 28, 2020 after receipt of consideration, post necessary regulatory approvals and approval of shareholders of the Company at the Extra-ordinary General Meeting held on February 13, 2020.

Other Income for the year ended March 31, 2020 includes a net amount of Rs. 18.31 crores in relation to the divestiture of stake held by the Company directly.

9. Exceptional items for the period ended September 30, 2020

Exceptional items for the period ended September 30,2020 include write off of certain property plant and equipment and intangible assets under development pertaining to Mumbai R & D center, aggregating to Rs. 37.42 crores.



10. The Company has exercised the option of lower tax permitted under Section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019 ('the Amendment Act'). Accordingly, the Company had recognised provision for income tax for the year ended March 31, 2020 basis the rate provided in the said Amendment Act. The Company had re-measured the opening balance of Deferred Tax Assets (net) including Minimum Alternate Tax (MAT) as at April 1, 2019 and accounted net tax expense of Rs. 385.62 crores relating to the same in the year ended March 31,2020.
11. During the year ended March 31, 2020, the Company has sold its entire direct investment of 9.96% in Shriram Transport Finance Company Limited. Upon sale, the Company has reclassified the cumulative fair value changes of Rs. 670.40 crores from Other Comprehensive Income to Retained Earnings.
12. The National Company Law Tribunal has approved a "Scheme of Amalgamation" ("Scheme") of Piramal Phytocare Limited ("Transferor company"), an associate of the Company, with the Company and its respective shareholders vide it's order dated November 4, 2019. Pursuant to the necessary filings with Registrar of Companies, Mumbai, the Scheme has become effective from December 2, 2019 with the appointed date of April 1, 2018. Accordingly the results for the six months and three months ended September 30,2019, have been restated for the accounting impact of merger, as if the merger had occurred from the beginning of the comparative period. The impact of merger is not significant on the results and EPS of the Company.
13. The Company transferred certain financial assets to wholly owned subsidiaries as detailed below.

Entities	(Rs. in Crores)		
	For the three months ended 30/09/2019	For the six months ended 30/09/2019	Previous year ended 31/03/2020
Piramal Capital and Housing Finance Limited	992.42	1,897.09	1,897.09
PHL Fininvest Private Limited	-	198.18	198.18
Aggregate consideration	992.42	2,095.27	2,095.27

Accordingly, the results for three months and six months ended September 30,2019 and year ended March 31, 2020 are not comparable with the results of the periods presented.

14. In accordance with Ind AS 108 'Operating Segments', segment information has been given in the consolidated financial results of the Company and therefore, no separate disclosure on segment information is given in standalone financial results.

For **PIRAMAL ENTERPRISES LIMITED**



Ajay G. Piramal
Chairman

October 28, 2020, Mumbai

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

**TO THE BOARD OF DIRECTORS OF
PIRAMAL ENTERPRISES LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **PIRAMAL ENTERPRISES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its associates and joint ventures for the quarter and six months ended September 30, 2020 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the entities listed in Annexure I.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. As more fully described in Note 9 (a) to the Statement, to assess the recoverability of certain assets, the Group has considered internal and external information upto the date of this report in respect of the current and estimated future global including Indian economic indicators consequent to the global health pandemic. The actual impact of the pandemic may be different from that considered in assessing the recoverability of these assets. Our conclusion on the Statement is not modified in respect of this matter.

7. We did not review the interim financial information of nine subsidiaries included in the unaudited consolidated financial results, whose interim financial information reflect total assets of Rs. 70,142 crores as at September 30, 2020 and, total revenues of Rs. 2,365.63 crores and Rs. 4,627.68 crores for the quarter and six months ended September 30, 2020 respectively, total net profit after tax of Rs. 505.50 crores and Rs. 966.88 crores for the quarter and six months ended September 30, 2020 respectively and total comprehensive income of Rs. 466.99 crores and Rs. 911.03 crores for the quarter and six months ended September 30, 2020 respectively and net cash flows of Rs. 74.83 crores for the six months ended September 30, 2020, as considered in the Statement. The unaudited consolidated financial results also includes the Group's share of profit after tax and Total comprehensive income of Rs. 27 crores and Rs. 51.22 crores for the quarter and six months ended September 30, 2020 respectively, as considered in the Statement, in respect of one joint venture and one associate, whose interim financial information have not been reviewed by us. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint venture and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

8. The unaudited consolidated financial results includes the interim financial information of 29 subsidiaries which have not been reviewed or audited by their auditors, whose interim financial information reflect total assets of Rs. 8,908.42 crores as at September 30, 2020 and, total revenue of Rs. 353.84 crores and Rs. 620.42 crores for the quarter and six months ended September 30, 2020 respectively, total profit after tax of Rs. 37.93 crores and Rs. 25.40 crores for the quarter and six months ended September 30, 2020 respectively and Total comprehensive income of Rs. 48.29 crores and Rs. 52.66 crores for the quarter and six months ended September 30, 2020 respectively and net cash flows of Rs. 205.11 crores for the six months ended September 30, 2020, as considered in the Statement. The unaudited consolidated financial results also includes the Group's share of profit and total comprehensive income of Rs. 23.24 crores and Rs. 33.95 crores for the quarter and six months ended September 30, 2020 respectively, as considered in the Statement, in respect of two associates and eight joint ventures, based on their interim financial information which have not been reviewed or audited by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Rupen K. Bhatt
Partner
(Membership No. 046930)

Place: Mumbai
Date: October 28, 2020

ANNEXURE I TO THE INDEPENDENT AUDITOR'S REVIEW REPORT

(Referred to in paragraph 4 under Independent Auditor's Review Report of even date)

S.N. Particulars

Parent

1 Piramal Enterprises Limited

List of Subsidiaries

- 2 PHL Fininvest Private Limited
- 3 Piramal International
- 4 Piramal Holdings (Suisse) SA
- 5 Piramal Dutch Holdings N.V.
- 6 Piramal Critical Care Italia, S.P.A
- 7 Piramal Critical Care Deutschland GmbH
- 8 Piramal Critical Care B.V.
- 9 Piramal Healthcare (Canada) Limited
- 10 Piramal Critical Care Limited
- 11 Piramal Critical Care South Africa (Pty) Ltd
- 12 Piramal Critical Care Pty. Ltd
- 13 Piramal Healthcare UK Limited
- 14 Piramal Healthcare Pension Trustees Limited
- 15 Piramal Healthcare Inc.
- 16 Piramal Critical Care Inc.
- 17 Piramal Pharma Inc.
- 18 PEL Pharma Inc.
- 19 Piramal Pharma Solutions Inc.
- 20 Ash Stevens LLC
- 21 Piramal Dutch IM Holdco B.V.
- 22 PEL-DRG Dutch Holdco B.V.
- 23 Piramal Fund Management Private Limited
- 24 INDIAREIT Investment Management Co.
- 25 Piramal Asset Management Private Limited
- 26 Piramal Capital and Housing Finance Limited
- 27 Piramal Investment Advisory Services Private Limited
- 28 Piramal Investment Opportunities Fund
- 29 Piramal Systems & Technologies Private Limited
- 30 Piramal Technologies SA
- 31 PEL Finhold Private Limited
- 32 Piramal Consumer Products Private Limited
- 33 Piramal Securities Limited
- 34 Piramal Asset Management Private Limited (Singapore)
- 35 Piramal Pharma Solutions B.V.
- 36 Piramal Capital International Limited
- 37 Piramal Pharma Limited
- 38 PEL Healthcare LLC (w.e.f. June 26, 2020)
- 39 Piramal Finance Sales and Services Private Limited

Deloitte Haskins & Sells LLP

List of Associates

- 40 Allergan India Private Limited
- 41 Shriram Capital Limited
- 42 Bluebird Aero Systems Limited

List of Joint Ventures

- 43 Shrilekha Business Consultancy Private Limited
- 44 Convergence Chemicals Private Limited
- 45 India Resurgence ARC Private Limited
- 46 India Resurgence Asset Management Business Private Limited
- 47 Asset Resurgence Mauritius Manager
- 48 Piramal Ivanhoe Residential Equity Fund 1
- 49 India Resurgence Fund - Scheme 2
- 50 India Resurgence ARC trust I
- 51 Piramal Structured Credit Opportunities Fund

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2020

(Rs. in Crores)

Particulars	Three months ended 30/09/2020	Three months ended 30/06/2020	Corresponding Three months ended 30/09/2019	Year to date figures for current period ended 30/09/2020	Year to date figures for previous period ended 30/09/2019	Previous year ended 31/03/2020
	(Unaudited)	(Unaudited)	(Unaudited) (Refer note 11 &16)	(Unaudited)	(Unaudited) (Refer note 11 &16)	(Audited)
Revenue from operations	3,301.84	2,937.34	3,270.50	6,239.18	6,457.32	13,068.29
Other income (Net) (Refer Note 15)	37.55	65.46	45.90	103.01	110.19	491.11
Total Income	3,339.39	3,002.80	3,316.40	6,342.19	6,567.51	13,559.40
Expenses						
Cost of materials consumed	417.91	361.59	473.95	779.50	744.16	1,377.19
Purchases of stock-in-trade	109.90	116.97	30.04	226.87	166.53	473.45
Changes in inventories of finished goods, stock-in-trade and work-in-progress	(85.16)	(175.54)	(68.24)	(260.70)	(150.62)	(173.82)
Employee benefits expense	402.85	411.74	400.18	814.59	794.80	1,610.20
Finance costs	1,155.75	1,104.56	1,336.94	2,260.31	2,665.49	5,320.62
Depreciation and amortisation expense	139.36	134.64	128.37	274.00	249.75	520.30
Expected credit loss on financial assets (including commitments) (Refer Note 9 (b))	23.92	50.77	(107.16)	74.69	(151.79)	1,874.72
Other expenses (Net)	432.43	376.35	352.11	808.78	807.83	1,639.18
Total Expenses	2,596.96	2,381.08	2,546.19	4,978.04	5,126.15	12,641.84
Profit before share of net profit of associates and joint ventures, exceptional items and tax	742.43	621.72	770.21	1,364.15	1,441.36	917.56
Share of net profit of associates and joint ventures	50.24	34.93	96.10	85.17	168.99	489.56
Profit after share of net profit of associates and joint ventures before exceptional items and tax	792.67	656.65	866.31	1,449.32	1,610.35	1,407.12
Exceptional items (Refer Note 10)	39.49	-	-	39.49	-	-
Profit after share of net profit of associates and joint ventures and before tax	832.16	656.65	866.31	1,488.81	1,610.35	1,407.12
Tax Expense						
(1) Current tax (including tax expense of prior years)	70.70	52.50	99.67	123.20	408.27	355.81
(2) Deferred tax (Net)	133.15	108.59	158.45	241.74	65.36	(152.97)
(3) Tax adjustment for earlier years (Refer Note 12)	-	-	-	-	-	1,757.59
Profit/(Loss) from continuing operations after tax and share of profit of associates and joint ventures	628.31	495.56	608.19	1,123.87	1,136.72	(553.31)
Profit/(Loss) from discontinued operations						
Profit / (loss) of discontinued operations (Refer Note 11)	-	-	(55.02)	-	(133.33)	(131.74)
Gain on disposal of Healthcare Insights & Analytics group (net of transaction cost)	-	-	-	-	-	757.48
Tax expense on above	-	-	1.80	-	3.85	51.29
Profit/(Loss) from discontinued operations after tax	-	-	(56.82)	-	(137.18)	574.45
Profit for the period	628.31	495.56	551.37	1,123.87	999.54	21.14
Other Comprehensive Income and (Expense) (OCI)						
A. Items that will not be reclassified to profit or loss						
(a) Changes in fair values of equity instruments through OCI	182.50	(50.70)	(184.55)	131.80	(969.54)	(1,359.46)
(b) Remeasurement of post employment benefit plans	(0.31)	(0.05)	(0.21)	(0.36)	(3.01)	(4.20)
Income tax impact on above	0.14	-	0.16	0.14	1.15	1.05
B. Items that will be subsequently reclassified to profit or loss						
(a) Deferred losses on cash flow hedge	16.23	(4.56)	(6.73)	11.67	(35.67)	(46.75)
(b) Deferred gains / (losses) on cash flow hedge of discontinued operations	-	-	(0.87)	-	(11.11)	3.92
(c) Exchange differences on translation of financial statements of foreign operations	(66.97)	4.42	38.31	(62.55)	25.34	372.97
(d) Exchange differences on translation of discontinued operation	-	-	92.67	-	82.56	115.83
(e) Gain of bargain purchase (Refer note 6)	11.69	-	-	11.69	-	-
(f) Share of other comprehensive income of associates and joint ventures	-	-	-	-	-	-
Income tax impact on above	1.07	2.08	(26.17)	3.15	(22.03)	(36.64)
Total Other Comprehensive Income/ (Expense), net of tax expense	144.35	(48.81)	(87.39)	95.54	(932.31)	(953.28)



Particulars	Three months ended 30/09/2020	Three months ended 30/06/2020	Corresponding Three months ended 30/09/2019	Year to date figures for current period ended 30/09/2020	Year to date figures for previous period ended 30/09/2019	Previous year ended 31/03/2020
	(Unaudited)	(Unaudited)	(Unaudited) (Refer note 11 &16)	(Unaudited)	(Unaudited) (Refer note 11 &16)	(Audited)
Total Comprehensive Income/ (Loss), net of tax expense	772.66	446.75	463.98	1,219.41	67.23	(932.14)
Profit / (Loss) attributable to:						
Owners of Piramal Enterprises Limited	628.31	495.56	551.98	1,123.87	1,001.01	24.03
Non-Controlling interests	-	-	(0.61)	-	(1.47)	(2.89)
Other Comprehensive Income/ (Expense) attributable to:						
Owners of Piramal Enterprises Limited	144.35	(48.81)	(87.39)	95.54	(932.31)	(953.28)
Non-Controlling interests	-	-	-	-	-	-
Total Comprehensive Income/ (Loss) attributable to:						
Owners of Piramal Enterprises Limited	772.66	446.75	464.59	1,219.41	68.70	(929.25)
Non-Controlling interests	-	-	(0.61)	-	(1.47)	(2.89)
Total Comprehensive Income / (Loss) attributable to owners of Piramal Enterprises Limited:						
Continuing operations	772.66	446.75	429.00	1,219.41	132.96	(1,626.34)
Discontinued operations	-	-	35.59	-	(64.26)	697.09
Paid-up Equity Share Capital (Face Value of Rs.2/- each)	45.11	45.11	39.77	45.11	39.77	45.11
Reserves (excluding Revaluation Reserves)						30,526.48
Earnings Per Equity Share (EPS) (Face Value of Rs.2/- each) (not annualised)						
For continuing operations						
a) Basic EPS for the period/year (Rs.)	26.50	20.90	29.85	47.40	55.80	(26.25)
b) Diluted EPS for the period/year (Rs.)	26.26	20.71	29.76	46.97	55.62	(26.25)
For discontinued operations						
a) Basic EPS for the period/year (Rs.)	-	-	(2.76)	-	(6.66)	27.39
b) Diluted EPS for the period/year (Rs.)	-	-	(2.75)	-	(6.64)	27.39
For continuing and discontinued operations						
a) Basic EPS for the period/year (Rs.)	26.50	20.90	27.09	47.40	49.14	1.14
b) Diluted EPS for the period/year (Rs.)	26.26	20.71	27.01	46.97	48.98	1.14

See accompanying notes to the Consolidated financial results

Additional Information:

The following additional information is presented to disclose the effect on net profit/ (loss) from continuing operation after tax and share of profits of associates and joint ventures, Basic and Diluted EPS, without the effect of tax adjustment of prior year (Refer note 12).

Particulars	(Rs. in Crores)	
	Previous year ended 31/03/2020	
Profit/(loss) from continuing operation after tax and share of profit of associates and joint ventures As reported in the consolidated financial results Add: Impact of Tax adjustment of prior years (Refer Note 12)	(553.31)	1,757.59
Adjusted Profit from continuing operations after tax and share of profit of associates and joint ventures	1,204.28	
Basic EPS for the period/ Year (Rs.) As reported in the consolidated financial results Add: Impact of Tax adjustment of prior years (Refer Note 12)	(26.25)	83.39
Adjusted Basic EPS (Rs.)	57.14	
Diluted EPS for the period/ Year (Rs.) As reported in the consolidated financial results Add: Impact of Tax adjustment of prior years (Refer Note 12)	(26.25)	83.15
Adjusted Diluted EPS (Rs.)	56.90	



Piramal Enterprises Limited

CIN : L24110MH1947PLC005719

Registered Office: Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai 400 070 India
Secretarial Dept : Ground Floor, B Block, Agastya Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, Maharashtra 400070, India
T +91 22 3802 3084/3083/3103 F +91 22 3802 3084

piramal.com

Notes:

1. The unaudited consolidated financial results for the three and six months ended September 30, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 28, 2020. The Statutory Auditors of the Group have carried out a limited review of these results.

2. Statement of Consolidated Assets and Liabilities:

Particulars	(Rs. in Crores)	
	As at	
	30/09/2020 (Unaudited)	31/03/2020 (Audited)
ASSETS		
1. Non-Current Assets		
(a) Property, Plant & Equipment	2,528.81	2,432.90
(b) Right-of-use assets	159.07	181.65
(c) Capital work in progress	351.49	266.12
(d) Goodwill	1,112.70	1,139.07
(e) Other Intangible Assets	2,593.26	2,661.85
(f) Intangible Assets under development	195.03	250.99
(g) Financial Assets:		
(i) Investments		
- Investments accounted for using the equity method	4,206.85	4,218.24
- Other Investments	10,737.69	12,274.16
(ii) Loans	27,218.15	31,304.48
(iii) Other Financial Assets	1,448.87	549.55
(h) Deferred Tax Assets (Net)	2,155.72	2,372.32
(i) Other Non-Current Assets	1,360.95	1,144.17
Total Non-Current Assets	54,068.59	58,795.50
2. Current Assets		
(a) Inventories	1,413.26	1,061.17
(b) Financial Assets:		
(i) Investments	4,433.77	2,950.39
(ii) Trade Receivables	1,063.20	1,324.39
(iii) Cash & Cash Equivalents	5,578.14	4,340.94
(iv) Bank Balances other than (iii) above	376.55	430.18
(v) Loans	8,110.18	4,075.79
(vi) Other Financial Assets	709.15	1,118.23
(c) Other Current Assets	923.37	801.99
(d) Asset classified as held for sale	-	10.00
Total Current Assets	22,607.62	16,113.08
Total Assets	76,676.21	74,908.58
EQUITY AND LIABILITIES		
1. Equity		
(a) Equity Share Capital	45.11	45.11
(b) Other Equity	31,430.35	30,526.48
Total Equity	31,475.46	30,571.59
2. Liabilities		
Non-Current Liabilities		
(a) Financial Liabilities:		
(i) Borrowings	26,446.13	20,306.25
(ii) Lease Liabilities	121.85	144.20
(iii) Other Financial Liabilities	-	0.72
(b) Provisions	55.37	65.21
(c) Deferred Tax Liabilities (Net)	25.74	8.22
(d) Other Non-Current Liabilities	138.39	139.39
Total Non-Current Liabilities	26,787.48	20,663.99
Current Liabilities		
(a) Financial Liabilities:		
(i) Borrowings	6,444.80	7,949.91
(ii) Trade Payables		
Total outstanding dues of Micro enterprises and small enterprises	8.77	12.26
Total outstanding dues of creditors other than Micro enterprises and small enterprises	1,298.40	977.57
(iii) Lease Liabilities	44.52	39.46
(iv) Other Financial Liabilities	10,026.22	14,077.00
(b) Other Current Liabilities	182.00	159.54
(c) Provisions	201.45	244.35
(d) Current Tax Liabilities (Net)	207.11	212.91
Total Current Liabilities	18,413.27	23,673.00
Total Equity & Liabilities	76,676.21	74,908.58

Notes:
3 Segment Wise Revenue, Results and Capital Employed
(Rs. in Crores)

Particulars	Three months ended 30/09/2020	Three months ended 30/06/2020	Corresponding Three months ended 30/09/2019	Year to date figures for current period ended 30/09/2020	Year to date figures for previous period ended 30/09/2019	Previous year ended 31/03/2020
	(Unaudited)	(Unaudited)	(Unaudited) (Refer note 11 &16)	(Unaudited)	(Unaudited) (Refer note 11 &16)	(Audited)
1. Segment Revenue						
Total Income from Operations, Net						
a. Pharmaceuticals	1,441.07	1,037.85	1,316.54	2,478.92	2,488.94	5,418.87
b. Financial services	1,860.77	1,899.49	1,953.96	3,760.26	3,968.38	7,649.42
Total Income from Operations (a + b)	3,301.84	2,937.34	3,270.50	6,239.18	6,457.32	13,068.29
2. Segment Results						
a(i). Pharmaceuticals	327.08	109.29	303.67	436.37	546.33	1,433.55
a(ii) Exceptional item (Refer note 10 (b))	(37.42)	-	-	(37.42)	-	-
a(iii). Pharmaceuticals (after exceptional item)	289.66	109.29	303.67	398.95	546.33	1,433.55
b. Financial services	603.72	626.14	735.46	1,229.86	1,469.82	355.30
Total (a + b)	893.38	735.43	1,039.13	1,628.81	2,016.15	1,788.85
Less: Depreciation and amortisation expense	139.36	134.64	128.37	274.00	249.75	520.30
Less: Finance costs (unallocated)	37.23	13.57	138.18	50.80	263.87	444.89
Add : Net unallocated income/(expense) (including exceptional gain (Refer note 10 (a)))	65.13	34.50	(2.37)	99.63	(61.17)	93.90
Total Profit Before Tax and share of net profit of associates and joint ventures, after exceptional items	781.92	621.72	770.21	1,403.64	1,441.36	917.56
3. Capital Employed (Segment Assets - Segment Liabilities)						
a. Pharmaceuticals						
Segment Assets	9,671.25	9,518.00	9,012.06	9,671.25	9,012.06	9,521.78
Segment Liabilities	(1,858.64)	(1,802.75)	(1,591.60)	(1,858.64)	(1,591.60)	(1,511.67)
b. Financial services						
Segment Assets	61,696.04	62,292.23	61,608.84	61,696.04	61,608.84	60,672.94
Segment Liabilities	(40,329.98)	(42,086.98)	(42,811.57)	(40,329.98)	(42,811.57)	(41,279.11)
c. Unallocated						
Segment Assets	5,308.92	6,201.90	5,263.94	5,308.92	5,263.94	4,713.86
Segment Liabilities	(3,012.13)	(3,104.06)	(10,190.83)	(3,012.13)	(10,190.83)	(1,546.21)
	31,475.46	31,018.34	21,290.84	31,475.46	21,290.84	30,571.59
Healthcare Insights & Analytics (Discontinued operations) (Refer note 11)						
Segment Assets	-	-	5,951.11	-	5,951.11	-
Segment Liabilities	-	-	(620.69)	-	(620.69)	-
Total Capital Employed	31,475.46	31,018.34	26,621.26	31,475.46	26,621.26	30,571.59

Information relating to discontinued operations as stated in Note 11 to the consolidated financial results:
(Rs. in Crores)

Particulars	Three months ended 30/09/2020	Three months ended 30/06/2020	Corresponding Three months ended 30/09/2019	Year to date figures for current period ended 30/09/2020	Year to date figures for previous period ended 30/09/2019	Previous year ended 31/03/2020
	(Unaudited)	(Unaudited)	(Unaudited) (Refer note 11 &16)	(Unaudited)	(Unaudited) (Refer note 11 &16)	(Audited)
1. Segment Revenue	-	-	333.21	-	652.43	1,354.78
2. Segment Results	-	-	64.42	-	103.48	328.35

Note:

Segment results of Pharmaceuticals and Healthcare Insights & Analytics segment represent Earnings before Interest, Tax, Depreciation and Amortisation and segment results of Financial services represent Earnings before Tax, Depreciation and Amortisation.



4 Unaudited Consolidated cashflow information:

Particulars	(Rs. in Crores)	
	Year to date figures for current period ended 30/09/2020	Year to date figures for previous period ended 30/09/2019
Cash flow from operating activities		
Profit before share of net profit of associates and joint ventures, exceptional items and tax	1,364.15	1,441.36
Loss before tax from discontinued operations (Refer note 11)	-	(133.33)
Operating Profit before working capital changes	1,769.51	1,858.73
A. Net Cash generated from Operating Activities	1,730.02	6,549.26
B. Net cash (used in)/ generate from investing	(1,029.82)	616.36
C. Net cash (used in)/ generated from financing activities	2,147.92	(5,414.44)
D. Effect of exchange differences on translation of foreign currency cash and cash equivalents	(8.51)	0.49
Net increase in Cash and Cash equivalents (A+B+C+D)	2,839.61	1,751.67
Cash and cash equivalents (Net of Bank Overdraft) at the beginning of the period	2,611.58	623.24
Cash balance acquired (Refer note 6)	0.89	-
Cash and cash equivalents (Net of Bank Overdraft) at the end of the period	5,452.08	2,374.91

5 Standalone Information:

Particulars	(Rs. in Crores)					
	Three months ended 30/09/2020	Three months ended 30/06/2020	Corresponding Three months ended 30/09/2019	Year to date figures for current period ended 30/09/2020	Year to date figures for previous period ended 30/09/2019	Previous year ended 31/03/2020
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1. Total Income	1,119.16	855.93	1,632.43	1,975.09	2,571.70	4,918.25
2. Profit before exceptional item and tax	158.66	27.06	645.55	185.72	545.57	539.84
3. Profit after tax	103.32	22.54	633.10	125.85	592.40	144.85

6 The Group, through its wholly owned subsidiary, PEL Pharma Inc, has acquired 100% stake in G&W PA Laboratories LLC (G&W PA) (now known as PEL Healthcare LLC) in an all cash deal for a total consideration of USD 17.5 million. Through this, the group has acquired the solid oral dosage drug product manufacturing facility of G&W PA, located in Sellersville, Pennsylvania. The transaction was closed on June 26, 2020 and the purchase price allocation is completed in the current quarter.

7 The Board of Directors ('Board') of the Company at their meeting held on June 26, 2020, had inter alia, approved:

- the sale/ transfer of the pharmaceutical business ('Pharma Business') of the Company, held by the Company directly and through its wholly owned subsidiaries, to Piramal Pharma Limited, wholly owned subsidiary of the Company ('PPL').
- the strategic growth investment by CA Clover Intermediate II Investments (now known as CA Alchemy Investments) ("Carlyle"), an affiliated entity of CAP V Mauritius Limited, an investment fund managed and advised by affiliated entities of The Carlyle Group Inc., for a 20% stake in the fresh equity capital of PPL.

This transaction was successfully closed on October 6th, 2020 on receipt of requisite approvals, As a result PPL, subsidiary of Piramal Enterprises Limited received INR 3,523.40 Crores towards 20% equity investment from CA Alchemy Investments.

8 Moratorium in accordance with the Reserve Bank of India (RBI) guidelines

The outbreak of Covid-19 pandemic across the globe & India has contributed to a significant decline and volatility in the global and Indian financial markets and slowdown in the economic activities. The RBI had issued guidelines relating to COVID-19 Regulatory Package dated March 27, 2020 and April 17, 2020 and in accordance therewith, the Group had offered a moratorium of three months on the payment of all principal instalments and/ or interest, as applicable, falling due between March 1, 2020 and May 31, 2020 to all eligible borrowers classified as standard, even if overdue as on February 29, 2020, excluding the collections made already in the month of March 2020. Further, in line with the additional Regulatory Package guidelines dated May 23, 2020 the Group granted a second three month moratorium on the payment of principal instalments and/ or interest, as applicable, falling due between June 1, 2020 and August 31, 2020. For all such accounts where the moratorium is granted, the asset classification will remain standstill during the moratorium period (i.e. the number of days past due shall exclude the moratorium period for the purposes of asset classification as per the policy).

9 Estimation of uncertainty relating to COVID-19 global health pandemic:

a. In assessing the recoverability of loans, receivables, intangible assets (including goodwill), deferred tax asset and investments, the Group has considered internal and external sources of information, including credit reports, economic forecasts and industry reports upto the date of approval of these consolidated financial results. The Group has performed sensitivity analysis on the assumptions used and based on current indicators of future economic conditions, the carrying amount of these assets represent the Group's best estimate of the recoverable amounts. As a result of the uncertainties resulting from COVID-19 and external developments, including the final decision of the Honourable Supreme Court in relation to moratorium and other related matters, the impact of this pandemic may be different from those estimated as on the date of approval of these financial results and the Group will continue to monitor any changes to the future economic conditions.

b. During the year ended March 31, 2020, The Group had estimated and recognised an additional expected credit loss of Rs. 1,903 Crores on certain financial assets, on account of the anticipated effect of the global health pandemic and for the quarter ended June 30, 2020, provision for expected credit loss of Rs. 46 Crores was made in line with RBI provisioning guidelines for moratorium.

10 In the Consolidated financial results, 'Exceptional item' for the quarter and six months ended September 30, 2020:

- Mark to market gains on forward contracts of Rs 76.91 Crores taken against expected equity investment inflow from Investors in Pharma segment.
- Write off of certain property plant and equipment and intangible assets under development pertaining to Mumbai R & D center, aggregating to Rs. 37.42 crores

11 During the previous year ended March 31, 2020, the Board of Directors of the Company, at their meeting held on January 17, 2020 approved the divestment of the entire stake in the Healthcare Insights and Analytics business (the "Transaction"), held by the Company directly and through its wholly owned subsidiaries, to Clarivate Analytics Plc. and its subsidiaries, for an aggregate consideration of approximately USD 950 million. Post the approval by shareholders of the Company at the Extra-ordinary General Meeting held on February 13, 2020 and receipt of necessary regulatory approvals, the Transaction was completed on February 28, 2020 (closing date). USD 900 million was received, on the closing date and the balance USD 50 million would be received at the end of twelve months from the closing of the transaction. Consequently, Profit before tax and tax expenses relating to the Healthcare Insights and Analytics business have been disclosed separately as Discontinued operations as part of the above results. Results for the quarter and six months ended September 30, 2019, have been represented in the Statement to give effect to the presentation requirements of Ind AS 105: Non-current Assets Held for Sale and Discontinued Operations.

12 The Company and some of its Indian subsidiaries had exercised the option of lower tax rate permitted under Section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019 ('the Amendment Act'). Accordingly, the Company and some of its Indian subsidiaries had recognised provision for income tax for the quarter and previous year ended March 31, 2020 basis the rate provided in the said Amendment Act. The Company has re-measured the opening balance of Deferred Tax Assets (net) including Minimum Alternate Tax (MAT) as at April 1, 2019 and accounted net tax expense of Rs. 1,757.59 crores relating to the same during the year ended March 31, 2020.



13 During the six months ended September 30, 2019, the Group has sold its entire direct investment of 9.96% in Shriram Transport Finance Company Limited. Upon sale, the Group has reclassified the cumulative Fair value changes of Rs. 615.70 crores from Other Comprehensive Income to Retained Earnings.

14 The secured listed non-convertible debentures of the Group aggregating Rs.7,310 Crores as on September 30, 2020 are secured against specified receivables and a first ranking pari passu mortgage over Specifically Mortgaged Property.

The Asset cover on the secured listed non-convertible debentures of the Group exceeds hundred percent of the principal amount of the said debentures.


15 Other income (net) includes the net effect of Foreign Exchange Gain:

Particulars	(Rs. in Crores)					
	Three months ended 30/09/2020	Three months ended 30/06/2020	Corresponding Three months ended 30/09/2019	Year to date figures for current period ended 30/09/2020	Year to date figures for previous period ended 30/09/2019	Previous year ended 31/03/2020
Exchange Gain/ (Loss), Net	6.75	7.56	(1.54)	14.31	6.78	30.87

16 The National Company Law Tribunal has approved a "Scheme of Amalgamation" ("Scheme") of Piramal Phytocare Limited ("Transferor company"), an associate of the Company, with the Company and its respective shareholders vide its order dated November 4, 2019 . Pursuant to the necessary filings with Registrar of Companies, Mumbai, the Scheme has become effective from December 2, 2019 with the appointed date of April 1, 2018.

Accordingly results for the quarter and period ended September 30, 2019, have been restated for the accounting impact of merger, as if the merger had occurred from the beginning of financial year ended March 31, 2019. The impact of merger is not significant on the results and EPS of the Company.

For **PIRAMAL ENTERPRISES LIMITED**



Ajay G. Piramal
Chairman

October 28, 2020, Mumbai

PRESS RELEASE

Piramal Enterprises Limited Announces Consolidated Results for Q2 & H1 FY2021

- *Resilient Performance despite a Challenging Business Environment Globally*
- *Net profit increased by 14% YoY to INR 628 Cr for Q2 FY21 and by 12% YoY to INR 1,124 Cr for H1 FY21*
- *Strengthened Balance Sheet and improved Liquidity position:*
 - *Raised Long-Term Borrowings of ~INR 11,500 Cr. during H1 FY2021*
 - *Received Growth Capital of INR 3,523.40 Cr. from The Carlyle Group in Piramal Pharma*

Mumbai, India | October 28, 2020: Piramal Enterprises Limited ('PEL', NSE: PEL, BSE: 500302, 912460) today announced its consolidated results for the Second Quarter (Q2) and Half Year (H1) ended September 30, 2020.

Consolidated Financial Highlights

- **Balance Sheet:**
 - Shareholders' Equity increased by 28% to INR 34,739 Cr.* since Mar 19
 - 39% reduction in Net Debt by nearly INR 22,000 Cr.* since Mar 2019
 - Net Debt-to-Equity of below 1x times* at entity-level*Post Pharma deal closed in October 2020
- **Inflows / Borrowings:**
 - Total inflows of ~INR 42,800 Cr. since April 2019, through equity and borrowing transactions
 - Raised long-term borrowings of ~INR 11,500 Cr. during H1 FY2021
 - Reduction in CPs to INR 2,100 Cr. as of Sep 2020 from INR 18,017 Cr. as of Sep 2018
- **P&L:**
 - Revenue for Q2 FY21 increased by 1% YoY to INR 3,302 Cr.
 - Net Profit for Q2 FY21 increased by 14% YoY to INR 628 Cr.
 - Net Profit for H1 FY21 grew by 12% YoY to INR 1,124 Cr.

Mr. Ajay Piramal, Chairman, Piramal Enterprises Ltd. said, "We have delivered a resilient performance with net profit of INR 1,124 Crore for H1 FY21, despite adverse global environment. Continuing to focus on strengthening our balance sheet, over the past year, we brought in INR 18,000 Cr of capital and reduced our net debt-to-equity ratio to below 1x.

In Financial Services, we saw early signs of recovery across the key sectors that we lend to. Progressing on the stated strategy of diversifying the loan book, we will be launching our multi-product retail lending platform in November 2020.

The Pharma Business recorded a healthy improvement in both revenue growth and profitability. It also completed the 20% growth investment by The Carlyle Group - which is an affirmation of the robustness of the business model and consistency in performance. Both businesses are now at an inflection point, where we see a good runway for strong performances in the mid to long-term."

Key Business Highlights	
Financial Services	Pharma
<ul style="list-style-type: none"> ▪ In line with our Strategy to diversify our book, launching the multi-product Retail Lending business in Nov-2020 ▪ Early trends indicate better performance of developer clients than assumed under stressed scenario for creating provisions ▪ Continue to increase granularity of our wholesale loan book. <ul style="list-style-type: none"> - Exposure to only one account at >15% of the net worth of Financial Services ▪ Conservative provisions of INR 3,037 Cr. as of Sep 2020, equivalent to 237% of GNPA's and 5.9% of overall loan book ▪ Capital Adequacy Ratio at 34% (vs. 22% as of March 2019) 	<ul style="list-style-type: none"> ▪ Closed fund raising deal with The Carlyle Group <ul style="list-style-type: none"> - Deal values our Pharma business at an Enterprise Value of USD 2.7 - 3.1 Bn. - Received INR 3523.40 Cr. as proceed from Pharma Fund raise. ▪ Revenue of INR 1,441 Cr. (+9% YoY) with EBITDA margins of 23% for Q2FY2021 <ul style="list-style-type: none"> - CDMO Revenue up 20% YoY - India Consumer Products up 25% YoY ▪ Other Highlights <ul style="list-style-type: none"> - CDMO order book witnessing healthy growth - India Consumer Products business launched 15 products and 38 SKUs during the year - Complex Hospital Generics now seeing recovery - Cleared 4 regulatory inspections

Business-wise Revenue Performance					(INR Crores or as stated)			
Net Sales break-up	Quarter II ended				Half year ended			
	30/9/20	30/9/19	% Change	% Sales	30/9/20	30/9/19	% Change	% Sales
Financial Services	1,861	1,954	-5%	56%	3,760	3,968	-5%	60%
Pharma	1,441	1,317	9%	44%	2,479	2,489	-	40%
<i>Pharma CDMO</i>	866	724	20%	26%	1,480	1,373	8%	24%
<i>Complex Hospital Generics</i>	438	477	-8%	13%	763	891	-14%	12%
<i>India Consumer Products</i>	140	112	25%	4%	244	222	10%	4%
Total	3,302	3,271	1%		6,239	6,457	-3%	

Consolidated Financial Performance (INR Crores or as stated)						
Particulars	Quarter II ended			Half year Ended		
	30-Sep-20	30-Sep-19	% Change	30-Sep-20	30-Sep-19	% Change
Net Sales	3,302	3,271	1%	6,239	6,457	-3%
Non-operating other income	38	46	-18%	103	110	-7%
Total income	3,339	3,316	1%	6,342	6,568	-3%
Other Operating Expenses	1,278	1,188	8%	2,369	2,363	0%
Expected Credit loss	24	-107		75	-152	
OPBIDTA	2,038	2,236	-9%	3,898	4,357	-11%
Interest Expenses	1,156	1,337	-14%	2,260	2,665	-15%
Depreciation	139	128	9%	274	250	10%
Profit / (Loss) before tax & exceptional items	742	770	-4%	1,364	1,441	-5%
Exceptional items (Expenses)/Income	39	0		39	0	
Income tax						
Current Tax and Deferred Tax	204	258	-21%	365	474	-23%
DTA and MAT Credit written off	0	0		0	0	
Profit/(Loss) after tax (before MI & Prior Period items)	578	512	13%	1,039	968	7%
Minority interest	0	0		0	0	
Share of Associates	50	96	-48%	85	169	-50%
Net Profit/(Loss) after Tax from continuing operations	628	608	3%	1,124	1,137	-1%
Profit / (Loss) from Discontinued operations	0	-57		0	-137	
Net Profit after Tax	628	551	14%	1,124	1,000	12%

Note: Figures in previous periods might have been regrouped or restated, wherever necessary to make them comparable to current period.

To download the results presentation and for further information on our financials, please visit our website: www.piramal.com

About Piramal Enterprises Ltd:

Piramal Enterprises Limited (PEL), a publicly listed company in India, has diversified business interests in Financial Services and Pharmaceuticals. PEL's consolidated revenues were ~US\$1.7 billion in FY2020, with ~34% of revenues generated from outside India.

In Financial Services, the Company offers a wide range of financial products and solutions, with exposure across both wholesale and retail financing. The wholesale lending business provides financing to real estate developers, as well as corporate clients in non-real estate sectors. Within retail lending, the Company offers housing loans to individual customers and is building a multi-product retail lending platform. India Resurgence Fund (IndiaRF), the distressed asset investing platform in partnership with Bain Capital Credit, invests in equity and/or debt across non-real estate sectors. The Company has long-standing partnerships with leading institutional investors that include - CPPIB, APG, Bain Capital Credit, CDPO, and Ivanhoe Cambridge. PEL also has equity investments in the Shriram Group, a leading financial conglomerate in India.

Piramal Pharma Limited (PPL), a subsidiary of PEL, offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 14 global facilities and a global distribution network in over 100 countries. PPL includes an integrated contract development and manufacturing (CDMO) business, Complex hospital generics business, and India Consumer Products business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, PPL received 20% strategic growth investment from the Carlyle Group.

For more information visit: www.piramal.com, [Facebook](#), [Twitter](#), [LinkedIn](#)

For Media Queries:

Dimple Kapur
Corporate Communications
Dimple.Kapur@piramal.com

For Investors

Hitesh Dhadha
Investor Relations
investor.relations@piramal.com

Piramal Enterprises Limited

Q2 & H1 FY2021 Results

28 October 2020



Key Highlights

PEL Consolidated

28% increase in Equity²
vs. Mar-19 to

INR
34,739 Cr.

39% reduction in Net Debt²
vs. Mar-19,
leading to a Net D/E of

0.96x

Total inflows³ since Apr-19
(incl. ~INR 18,000 Cr.
of capital inflows)

INR
42,800 Cr.

12% YoY increase in
H1 Net Profit to

INR
1,124 Cr.

Financial Services

Capital Adequacy Ratio

34%

Multi-product
Retail Lending platform

Launching
in Nov-20

237% provision coverage,
with total provision of

INR
3,037 Cr.

No. of exposures
>15% of net worth of
Financial Services

1

Pharma

Closed Pharma deal;
Business valued at an EV of

USD
2.7 - 3.1
billion

CDMO -
YoY Revenue growth
(Q2 FY21)

+20%

India Consumer Products -
YoY Revenue growth
(Q2 FY21)

+25%

EBITDA Margin
(Q2 FY21)

23%

Notes: (1) Above data points as of Sep-2020 or for Q2 / H1 FY21


(2) Equity and Net Debt values post Pharma deal (closed in Oct-2020)

(3) Including long-term borrowings and equity transactions

Revenues and Net Profits

Total Revenues^{1,2}


6-year CAGR: 21%



(In INR Crores)

Net Profit³

6-year CAGR: 50%



Company delivered a resilient performance in H1 FY2021, despite COVID-19 impact


Notes: (1) FY2015 results have been prepared based on IND GAAP and FY2016 onwards on IndAS basis

(2) Revenue for prior period excludes revenue from Healthcare Insights & Analytics


(3) FY18 Net profit excludes loss on sale of Imaging business; FY15 Net profit excludes gain on sale of Vodafone investment

Balance Sheet Highlights

Overall Equity (INR Cr.)



Net Debt (INR Cr.)



Balance Sheet (INR Cr.)	As of Oct-20 ¹ (Post-Pharma deal)	As on Mar-19	Change
Equity	34,739	27,224	+28%
Net Debt	33,457	55,122	-39%

Note: (1) As of Oct 6th 2020 considering the net capital raise from The Carlyle Group in the Pharma business

Segment-wise equity allocation

(In INR Crores)

**Overall Equity
(Post-Pharma deal in Oct-2020)¹**

Pharma: 22%¹

Built a differentiated business, valued at an EV of USD 2.7 - 3.1 billion. Includes additional capital raise of INR 3,264 Cr. to target organic & inorganic growth opportunities in the Pharma space.

Unallocated equity: 23%


Primarily includes investments in Shriram, receivables from DRG sale

Deferred Tax Asset: 6%

Financial Services (Lending): 48%

237% Provision Coverage Ratio, with provisions of INR 3,037 Cr.; and Capital Adequacy Ratio of 34%

**Overall Equity:
INR 34,739 Cr.**



**Equity of ~INR 25,000 Cr. available for Financial Services business to tap organic and inorganic opportunities
Among top-3 NBFCs² in India, in terms of equity capital available for the Financial Services business**

Notes: (1) As of Oct 6th, considering the net capital raise from The Carlyle Group of INR 3,264 in the Pharma business
NBFCs/infrastructure finance companies

(2) Comparison with sizeable NBFCs/HFCs; excluding government-owned

Borrowings and capital inflows

Inflows¹ since the beginning of FY20

- **Inflows of INR 42,800 Cr.** since the beginning of FY20, through borrowings and equity transactions
 - **Raised INR 11,500 Cr.** of long-term borrowings¹ in H1 FY2021

Gross inflows since Apr-2019 (INR Cr.)	Borrowings	Equity / Other inflows
Long-term borrowings ¹	20,900	-
Securitization	3,900	-
Stake sale in STFC	-	2,300
Rights Issue	-	3,650
Preferential Allotment	-	1,750
Sale of DRG	-	6,800
Pharma fund raise		3,500
Total	24,800	18,000
Grand Total	42,800	

Notes: (1) Long-term borrowings of ≥1 year tenure rounded-off (up to 2 digits)


(2) Figures in the table above have been rounded-off (up to 2 digits)

Reduction in short-term borrowings

- **Significant reduction in Commercial Papers (CPs) exposure**
 - Exposure to CPs declined to INR 2,100 Cr. from INR 18,017 Cr. in Sep-2018

CP exposure

(in INR Cr.)






Financial Services

Loan Book and Total Income


Loan book ¹ (in INR Crores)

8-year CAGR: 68%



Income from Financial Services (in INR Crores)

8-year CAGR: 49%






Wholesale Lending


Residential RE industry trends: Recovery in performance during Q2

No. of housing units sold (industry-wide)


Jan-Mar'20 Apr-Jun'20 Jul-Sep'20



Q2 FY21 sales as a % of Q4 FY20 sales



Residential RE prices – YoY Change




Prices remain range-bound, however, developers are offering flexibility in payment schedules

Industry-wide residential RE sales have recovered to 67% of pre-COVID levels in Q2 FY21

Significant consolidation taking place in the real estate sector

Industry-wide decline in the number of developers since 2012¹



Total number of developers in the top-14 Indian cities has already shrunk by 53% since 2012

Performance of PEL’s Developer Clients

Performance of our developer clients in Sep-20



Sales

- Sales of developers **back to 100% of pre-COVID levels**



Collections

- Developer collections from homebuyers at **82% of pre-COVID levels**



Construction

- Construction **commenced at nearly 100% of sites**



Labor

- **~90% (~21,000 laborers) returned** to sites vs. pre-COVID levels

Factors driving residential real estate sales


- ✓ Changing customer preferences and need for larger homes
- ✓ Townships gaining higher interest
- ✓ Demand for ready-to-move-in apartments
- ✓ Discounts being offered by some developers
- ✓ Regulatory support by governments / regulators
- ✓ Recent decline in home loan interest rates
- ✓ Organized developers leveraging technology to drive sales

Early trends indicate better performance of developer clients than assumed under stressed scenario for creating provisions

Increasing granularity of the loan book


(in INR Crores, unless otherwise stated)

Wholesale Loan Book




- 11% reduction since Mar-2019, which includes real estate and corporate loans

Top-10 exposures



- Exposure to top-10 accounts reduced 20% since Mar-2019 (~INR 3,700 Crores)

Single-borrower exposures



- Only one account exceeding the 15% net worth threshold



Retail Lending

Retail Lending strategy

A Product Strategy

- **Pivot** from ‘Affluent Housing’ to ‘Mass Affluent’ & ‘Affordable’ Housing
- Build a largely **secured lending book in FY21**, roll-out other lending products in FY22+

B Geography Selection

- **‘Bharat’**– Tier 2/3 locations in small & mid-market India (population 10,000 to 4m)
- **Hub and spoke model** with tech led spokes

C Partnerships

- **Strategic partnerships** for customer access at scale, distribution, and data access
- **Phygital**: Digital-at-the-core augmented with physical channels

D Operating Model & Talent

- **Agile mode** of working by operating teams
- **Minimum Viable Product (MVP)** approach
- Onboarding **top-quality talent**

E Technology Infrastructure


- Assembling a future-ready tech stack
- Combination of **off-the-shelf and internally engineered technology**
- **Cloud native, AI/ML¹ ready** from Day-1

F Credit Risk Management

- Building a credit risk management **framework for the post-COVID era**
- **Analytics woven deeply** into the fabric of business


Building a multi-product retail lending platform – ‘digital at its core’

Taking a differentiated approach to Retail Lending



Experienced, diverse and tech native management team to drive execution

Retail Lending: Progress and key milestones






Asset Quality

Conservative provisioning to mitigate any contingencies from COVID-19, etc.

Total Provisions

In INR Crores



	Sep-19	Sep-20
Total provision as a % of GNPA's	194%	237%
Provision Coverage – Stage 1 & 2	1.5%	5.1%
Total provision as a % of loan book	1.8%	5.9%

Overall provisioning:

- **Total provisions of INR 3,037 Cr.,** equivalent to **237% of GNPA's** and **5.9% of overall loan book**

Provisioning for Standard Assets

(Stage 1 & 2 loans):

- **Significantly increased to INR 2,542 Cr.** from INR 780 Cr. as of Sep-19
- **Provisions against Stage 1 & 2 loans at 5.1%** as of Sep-20


Note: Stage 1 - Loans which are less than or equal to 30 days past due (dpd); Stage 2 – Loans which are 31-90 dpd; and Stage 3 – Loans which are 90+ dpd

Liabilities


Borrowing mix

As on Sep 30, 2020

Breakdown of borrowing mix by type of instrument



Breakdown of borrowing mix by type of investor




Constantly diversifying borrowing profile across instruments and investor categories

Note: Data for PEL (excl. Pharma Business)

Asset-liability profile

(in INR crores)

As on Sep 30, 2020^{1,2}



Cumulative GAP³ (%)



Significant positive ALM GAP across all buckets


Notes: (1) Data for PEL (excl. Pharma Business)

(2) ALM assumes closure of Carlyle deal


(3) Cumulative GAP (%) = Net flows (i.e. cumulative inflows – cumulative outflows) as a % of cumulative outflows

Capital Adequacy and Leverage

Capital Adequacy Ratio (%)^{1,2}



Net Debt-to-Equity²



Significantly strengthened the capital adequacy through additional capital allocation and deleveraging

Performance metrics

Key Performance Indicators: PEL Financial Services

Particulars	H1 FY2021
Total Loan Book size	INR 51,522 Cr.
Total Equity on Lending (utilized synergies from reverse merger)	INR 16,775 Cr.
Net Debt	INR 34,634 Cr.
Net Debt-to-Equity	2.1x
Average Yield on Loans	14.8%
Average Cost of Funds	8.5%
Average Cost of Borrowings	10.8%
Net Interest Margin	6.3%
Cost to Income Ratio (CIR)	17.4%
Total Provisioning as a % of loan book (as on Sep 30, 2020)	5.9%
Gross NPA ratio (based on 90 dpd)	2.5%
Net NPA ratio	1.6%
ROA ¹	3.8%
ROE ¹	12%

Note: (1) Considering cash-tax, ROA is 4.7% and ROE is 15%

Financial Services: Key strategic priorities

- 1 Increasing granularity of the loan book
- 2 Taking proactive corrective actions to mitigate potential risks
- 3 Building a digitally-led, multi-product retail lending platform
- 4 Focused on developing fund-based platforms
- 5 Conservative provisioning to manage any contingences
- 6 Increasing share of long-term borrowings in overall borrowing mix

Pharma

Pharma Equity Capital Raise

Closed one of the largest PE deals in the Indian pharma sector with The Carlyle Group



USD 490m raised as fresh equity **for a 20% stake** in the Pharma business, valuing it at an **EV of USD 2,775m**.
In addition, an **upside component of up to USD 360m** depending on FY21 performance.



The partnership is an **affirmation of the strength of our ability** to build new, attractive, scalable and sustainable businesses



Oct-2020 - Completed 20% strategic growth investment by The Carlyle Group; received INR 3,523.40 Crores on closure



The deal **further strengthens the Company's balance sheet**




To accelerate **organic and inorganic growth plans** going forward

Re-built a differentiated Pharma business valued at an Enterprise Value (EV) of USD 2.7 - 3.1 billion

Resilient revenue performance

Consistent Revenue growth



- **Delivered revenue of INR 1,441 Cr. (+9% YoY) in Q2, contributing 44% to PEL’s overall revenue.**
 - **CDMO:** INR 866 Cr. (+20% YoY)
 - **Complex Hospital Generics:** INR 438 Cr. (-8% YoY)
 - **India Consumer Products:** INR 140 Cr. (+25% YoY)
- **Complex Hospital Generics now seeing recovery** as demand for products used in surgical procedures improves
- **EBITDA of INR 327 Cr. with EBITDA margins at 23%**
 - **Margins improve** due to higher revenues and cost rationalization
- Continued culture of strong Quality & Compliances
 - **4 successful regulatory inspections** during Q2 FY21
 - Successfully cleared **36 USFDA inspections** since FY2012
- PEL has 49% stake in **Allergan India**
 - Revenue of INR 393 Cr. & net profit of INR 104 Cr. in FY20

Notes: (1) Pharma includes Pharma CDMO, Complex Hospital Generics and India Consumer Healthcare and foreign exchange income numbers for the prior periods are based on IGAAP

(2) Numbers for the period FY2016 - FY2020 are based on IND AS;

Key developments during the quarter

CDMO

- **Strong growth in development order book**
- **4 New Chemical Entities (NCE) approvals** supported during H1
- **Carefully managed operating costs** during period of uncertainty
- Ensured normal operations and supplies
- Opening held for recently acquired Sellersville facility

Complex Hospital Generics

- **Improving market demand** for products used in surgical procedures; uncertainty remains
- **Held or increased market share** in major product categories and across markets
- **Carefully managing operating costs**, while ensuring regular operations

India Consumer Products

- **Launched 15 products and 38 SKUs** in H1, including COVID protection range of Tri-activ disinfectant spray, sanitizers and masks
- **Enhanced focus on media and advertising**
- **Focus on E-commerce** and use of technology ensured resilient operations
- **Leveraged our field force and distribution network** to ensure timely supplies during the lockdowns

Key strategic priorities: Pharma

1 Delivering consistent revenue growth and improve profitability

2 Pursuing organic and inorganic growth opportunities leveraging fresh capital

- ✓ Capacity expansion across multiple sites
- ✓ Acquisitions of niche manufacturing capabilities for CDMO
- ✓ Add new complex hospital generics through in-licensing, acquisitions and capital investments
- ✓ Organically and inorganically add Consumer Healthcare products to further leverage India-wide distribution platform
- ✓ Exploring re-entry into Domestic Formulations

3 Maintaining robust quality culture across manufacturing/development facilities globally

4 Continued focus on patient needs, customer experience, and EHS initiatives



Financials

Diversified Revenue Mix

(In INR Crores or as stated)

Net Sales break-up	Quarter II ended			% Sales for Q2 FY2021	Half year ended			% Sales for H1 FY2021
	30-Sept-20	30-Sept-19	% Change		30-Sept-20	30-Sept-19	% Change	
Financial Services	1,861	1,954	-5%	56%	3,760	3,968	-5%	60%
Pharma	1,441	1,317	9%	44%	2,479	2,489	-	40%
Pharma CDMO	866	724	20%	26%	1,480	1,373	8%	24%
Complex Hospital Generics	438	477	-8%	13%	763	891	-14%	12%
India Consumer Products	140	112	25%	4%	244	222	10%	4%
Total	3,302	3,271	1%		6,239	6,457	-3%	

Note: Pharma revenue includes foreign exchange gains/losses

Consolidated Profit & Loss

(In INR Crores or as stated)

Particulars	Quarter II ended			Half year Ended		
	30-Sept-20	30-Sept-19	% Change	30-Sept-20	30-Sept-19	% Change
Net Sales	3,302	3,271	1%	6,239	6,457	-3%
Non-operating other income	38	46	-18%	103	110	-7%
Total income	3,339	3,316	1%	6,342	6,568	-3%
Other Operating Expenses	1,278	1,188	8%	2,369	2,363	0%
Expected Credit loss	24	-107		75	-152	
OPBIDTA	2,038	2,236	-9%	3,898	4,357	-11%
Interest Expenses	1,156	1,337	-14%	2,260	2,665	-15%
Depreciation	139	128	9%	274	250	10%
Profit / (Loss) before tax & exceptional items	742	770	-4%	1,364	1,441	-5%
Exceptional items (Expenses)/Income	39	0	0%	39	0	0%
Income tax						
Current Tax and Deferred Tax	204	258	-21%	365	474	-23%
Profit / (Loss) after tax (before MI & Prior Period items)	578	512	13%	1,039	968	7%
Minority interest						
Share of Associates ¹	50	96	-48%	85	169	-50%
Net Profit / (Loss) after Tax from continuing operations	628	608	3%	1,124	1,137	-1%
Profit / (Loss) from Discontinued operations ²		(57)			(137)	
Net Profit after Tax	628	551	14%	1,124	1,000	12%

- Income under share of associates primarily includes our share of profits at Shriram Capital and profit under JV with Allergan, as per the accounting standards.
- Profit / (Loss) from Healthcare Insights & Analytics business, sold in Jan'20.

Consolidated Balance Sheet

(In INR Crores)


Particulars	As on Sep 30 th , 2020
Equity Share Capital	45
Other Equity	31,430
Non Controlling Interests	-
Borrowings (Current & Non Current)	42,675
Deferred Tax Liabilities (Net)	26
Other Liabilities	2,242
Provisions	257
Total	76,676
PPE, Intangibles (Under Development), CWIP	5,828
Goodwill on Consolidation	1,113
Financial Assets	
Investment	19,378
Others	28,667
Other Non Current Assets	1,361
Deferred Tax Asset (Net)	2,156
Current Assets	
Inventories	1,413
Trade receivable	1,063
Cash & Cash Equivalents & Other Bank balances	5,955
Other Financial & Non Financial Assets	9,743
Total	76,676

Note: Numbers from Ind-AS Financial Statements have been regrouped, wherever needed

Appendix

Developing fund-based platforms – Alternative AUM

Platform	JV Partner / Co-investor	Size / Initial Commitment
India RF – Stressed Asset Investing	Bain Capital	USD 629m
Mezzanine investments in Infra	APG	USD 375m ¹
Residential Real Estate platform	Ivanhoé Cambridge	USD 250m ²
Senior Debt in non-Real Estate, non-Infra sectors	CDPQ	USD 300m
InvIT platform for renewables	CPPIB	USD 600m ³



Notes: (1) Represents APG’s commitment; PEL has further committed USD 375m along-side these investments
50% to preferred transactions

(3) Initial targeted corpus of USD 600m; evaluating potential seed transactions

(2) Represents Ivanhoé Cambridge’s commitment, PEL to co-invest 25% to pure equity and
(4) Includes net AUM for the RE platform and the AUM for the platform with CDPQ

Stage-wise provisioning

Particulars (in INR Cr., unless otherwise stated)	As on Mar-2020	As on Jun-2020	As on Sep-2020
Gross Stage 1 & 2 Loans	49,761	49,984	50,243
Provision - Stage 1 & 2 loans	2,479	2,518	2,542
Provision Coverage Ratio - Stage 1 & 2	5.0%	5.0%	5.1%
Gross Stage 3 Loans (GNPAs)	1,202	1,281	1,279
GNPA Ratio (% of loans in Stage 3)	2.4%	2.5%	2.5%
Provision - Stage 3 loans	483	495	495
Provision Coverage Ratio - Stage 3	40%	39%	39%
Total Provision*	2,963	3,013	3,037
Total Loans	50,963	51,265	51,522
Total Provision / Total Loans	5.8%	5.9%	5.9%
Total Provision / GNPAs	246%	235%	237%

* Includes conservative provisions of INR 1,903 Cr. created in Q4 FY20 in response to COVID-19

Note: Stage 1 - Loans which are less than or equal to 30 days past due (dpd); Stage 2 – Loans which are 31-90 dpd; and Stage 3 – Loans which are 90+ dpd

Dial-in details for Q2 & H1 FY2021 Earnings Conference Call

Event	Location & Time	Telephone Number
Conference call on 28 th October, 2020	India – 5:30 PM IST	+91 22 6280 1264 / +91 22 7115 8165 (Primary Number) +91 70456 71221 (Local Number)
		1800 120 1221 / 1800 266 1221 (Toll free number)
	USA – 8:00 AM (Eastern Time – New York)	Toll free number 18667462133
	UK – 12:00 Noon (London Time)	Toll free number 08081011573
	Singapore – 8:00 PM (Singapore Time)	Toll free number 8001012045
	Hong Kong – 8:00 PM (Hong Kong Time)	Toll free number 800964448
For online registration	Please use this link for prior registration to reduce wait time at the time of joining the call – https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=9542403&linkSecurityString=1b3e46d1b2	

For Investors :

Hitesh Dhaddha

Chief Investor Relations Officer

Email : hitesh.dhaddha@piramal.com

Phone : +91 22 3046 6306

Aditya Sharma

Chief Manager – IR (Financial Services)

Email : investor.relations@Piramal.com

Phone : +91 22 3046 6305